A Phase I Open label, Dose Finding Study of IMCgp100 in Patients with Advanced Malignant Melanoma
What is the purpose of this trial?
This is a Phase 1, open-label, dose–finding study to assess the safety and tolerability of IMCgp100, a Monoclonal T Cell Receptor anti-CD3 scFv Fusion Protein, in patients with advanced malignant melanoma. Eligible patients will have Stage IV disease or unresectable Stage III disease.
- Last Updated:
- Study HIC#: